Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPMT | P51580 | 4/20 | 0.54 |
| ▸ | TTR | P02766 | 2/20 | 0.50 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MYC | P01106 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25981011 | 0.87 | CA12 (0.52) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL27300557 | 0.87 | TPMT (0.46) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL31701026 | 0.85 | TTR (0.52) | TPMTTTRHCAR1HSD17B10ALOX15 | |
| SCHEMBL31700656 | 0.85 | TPMT (0.45) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL2011060 | 0.85 | TPMT (0.45) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL15197099 | 0.82 | CA12 (0.58) | TPMTTTRCA12CA1CA2 | |
| SCHEMBL12983073 | 0.80 | CA5A (0.48) | ALDH1A1SMN1; SMN2TDP1CA5ALMNA | |
| SCHEMBL29710249 | 0.79 | TTR (0.56) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL5631374 | 0.79 | TTR (0.56) | TPMTTTRHCAR1CA12CA1 | |
| SCHEMBL1572119 | 0.79 | TPMT (0.59) | TPMTTTRHCAR1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735422-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | Sanofi (FR) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025006827-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | GENZYME CORPORATION (US) | 2025-01-02 | — | — | WO | disclosed |
| CN-112867705-B | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3774722-B1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE INC (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4302830-A2 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | Gilead Sciences, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3960735-B1 | QUINAZOLINE DERIVATIVES USED TO TREAT HIV | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230043136-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2023-02-09 | — | — | US | disclosed |
| US-20230043136-A1 | Quinazoline Compounds | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE AS CR, V.V.I. (CZ) | 2023-02-09 | — | — | US | disclosed |
| EP-1858850-A2 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1725537-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2006099060-A2 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006098982-A1 | PROCESS FOR THE PREPARATION OF OPIOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211863-A1 | Process for the preparation of opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| US-20060211861-A1 | Process for the preparation of opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-09-21 | — | — | US | disclosed |
| WO-2005090315-A1 | NOVEL COMPOUNDS AS OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203143-A1 | use as pain relievers, gastrointestinal disorders such as inflammatory bowel disease; compounds are aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid for example | JANSSEN PHARMACEUTICA, N. V. (BE) | 2005-09-15 | — | — | US | disclosed |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-03-24 | — | — | US | disclosed |
| EP-1206446-B1 | CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203143-A1 | use as pain relievers, gastrointestinal disorders such as inflammatory bowel disease; compounds are aminoacetamide derivatives substituted with an imidazole; 5-(([2-Amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino)-methyl)-2-methoxy-benzoic acid for example | OPRK1, OPRM1, OPRL1 | TPMT 196/4885TTR 4685/4885HCAR1 35/4885 |
| US-20060211861-A1 | Process for the preparation of opioid modulators | OPRM1, OPRK1, OPRL1 | TPMT 211/4885TTR 3397/4885HCAR1 351/4885 |
| US-20230043136-A1 | Quinazoline Compounds | TTBK1, TTBK2, MAPT | TPMT 159/4885TTR 1021/4885HCAR1 3895/4885 |
| US-11833142-B2 | 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | RXFP3, RXFP1, NPY2R | TPMT 497/4885TTR 252/4885HCAR1 254/4885 |
| US-20050065346-A1 | Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions | F12, F11, F2 | TPMT 1945/4885TTR 1194/4885HCAR1 144/4885 |
| US-20060211863-A1 | Process for the preparation of opioid modulators | OPRM1, OPRK1, OPRL1 | TPMT 211/4885TTR 3397/4885HCAR1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.